A slew of contemporary research suggests MDMA’s efficacy as an adjunct in the treatment of PTSD, while little is known concerning the mechanisms at work. Recent investigation into the behavioral neurobiology of MDMA’s ability to facilitate the cessation of fear responses may offer a mechanistic explanation regarding its psychiatric utility.
MDMA-assisted therapy has been on the forefront of psychedelic research for years, but more recently patient safety concerns and research ethics have come into question.
The potential use of serotonergic psychedelic drugs has yet to be explored for treatment of multimodal health issues such as obesity. A new preclinical study aims to explore the effects of psilocybin in rodent food consumption and weight gain.
Prior studies in clinical populations with OCD as well as animal models of this disorder indicate that psilocybin may suppress compulsive behavior. Although efforts to identify the mechanism of psilocybin’s effects are underway, the pharmacological targets underlying its anti-compulsive potential remain elusive.
Allosteric modulation is a promising way to target the receptors of psychoactive substances, such as CB1R, for therapeutic use. However, it is difficult to design safe, effective allosteric compounds. New high-resolution structures of CB1R provide insight into a way forward for drug discovery.
By engineering E. coli to produce norbaeocystin, researchers seek to settle whether this precursor to psilocybin is itself psychedelic.
The potential neurotoxicity of MDMA led to the development of APBs, a family of entactogens whose effect profiles may position them as attractive candidates for the next generation of entactogenic medicines.
Psychedelics have demonstrated the potential for rapid, dramatic, and enduring therapeutic effects in people with psychiatric disorders as well as in animal models of these conditions. However, the molecular adaptations in the brain that underlie these profound psychedelic-induced behavioral changes have yet to be defined.
We review the rise, fall, and rebirth of the infamous entactogen MDMA, the original ‘love drug’ and a promising tool for use in psychotherapy.
Previous research in people with substance use disorders and animal models of drug addiction indicate that classical psychedelics like LSD and psilocybin may reduce drug use and drug-seeking behavior. However, the mechanism of action underlying the anti-addictive effects of psychedelics remains unknown.